Aardvark Therapeutics, Inc. (AARD)

NASDAQ: AARD · Real-Time Price · USD
10.21
+0.39 (3.97%)
At close: May 28, 2025, 4:00 PM
10.21
0.00 (0.00%)
After-hours: May 28, 2025, 4:04 PM EDT
3.97%
Market Cap 221.52M
Revenue (ttm) n/a
Net Income (ttm) -27.72M
Shares Out 21.70M
EPS (ttm) -4.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,876
Open 10.00
Previous Close 9.82
Day's Range 9.99 - 10.41
52-Week Range 4.88 - 19.58
Beta n/a
Analysts Strong Buy
Price Target 31.25 (+206.07%)
Earnings Date May 14, 2025

About AARD

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2025
Employees 22
Stock Exchange NASDAQ
Ticker Symbol AARD
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AARD stock is "Strong Buy." The 12-month stock price forecast is $31.25, which is an increase of 206.07% from the latest price.

Price Target
$31.25
(206.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics t...

9 days ago - GlobeNewsWire

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term...

14 days ago - GlobeNewsWire

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics t...

21 days ago - GlobeNewsWire

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

2 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

Seven IPOs and three SPACs were listed this week. Seven IPOs and four SPACs submitted initial filings. Some small IPOs are tentatively scheduled for the short holiday week ahead.

3 months ago - Seeking Alpha

Aardvark Therapeutics Announces Pricing of Initial Public Offering

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic...

3 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial ...

3 months ago - Seeking Alpha

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

Aardvark Therapeutics aims to raise $100 million in an IPO to fund its clinical-stage biopharma treatments for metabolic conditions, including Prader-Willi syndrome. Its lead candidate ARD-101, target...

4 months ago - Seeking Alpha

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut

Aardvarks pipeline is headed up by ARD-101, a bitter taste receptor pan-agonist designed to stimulate enteroendocrine cells of the digestive tract.

4 months ago - Fierce Biotech

Aardvark Therapeutics IPO Registration Document (S-1)

Aardvark Therapeutics has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC